5KS5

Structure of the C-terminal Helical Repeat Domain of Elongation Factor 2 Kinase


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 400 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Structure of the C-Terminal Helical Repeat Domain of Eukaryotic Elongation Factor 2 Kinase.

Will, N.Piserchio, A.Snyder, I.Ferguson, S.B.Giles, D.H.Dalby, K.N.Ghose, R.

(2016) Biochemistry 55: 5377-5386

  • DOI: 10.1021/acs.biochem.6b00711

  • PubMed Abstract: 
  • Eukaryotic elongation factor 2 kinase (eEF-2K) phosphorylates its only known physiological substrate, elongation factor 2 (eEF-2), which reduces the affinity of eEF-2 for the ribosome and results in an overall reduction in protein translation rates. ...

    Eukaryotic elongation factor 2 kinase (eEF-2K) phosphorylates its only known physiological substrate, elongation factor 2 (eEF-2), which reduces the affinity of eEF-2 for the ribosome and results in an overall reduction in protein translation rates. The C-terminal region of eEF-2K, which is predicted to contain several SEL-1-like helical repeats (SLRs), is required for the phosphorylation of eEF-2. Using solution nuclear magnetic resonance methodology, we have determined the structure of a 99-residue fragment from the extreme C-terminus of eEF-2K (eEF-2K627-725) that encompasses a region previously suggested to be essential for eEF-2 phosphorylation. eEF-2K627-725 contains four helices, of which the first (αI) is flexible, and does not pack stably against the ordered helical core formed by the last three helices (αII-αIV). The helical core is structurally similar to members of the tetratricopeptide repeat (TPR) family that includes SLRs. The two penultimate helices, αII and αIII, comprise the TPR, and the last helix, αIV, appears to have a capping function. The eEF-2K627-725 structure illustrates that the C-terminal deletion that was shown to abolish eEF-2 phosphorylation does so by destabilizing αIV and, therefore, the helical core. Indeed, mutation of two conserved C-terminal tyrosines (Y712A/Y713A) in eEF-2K previously shown to abolish eEF-2 phosphorylation leads to the unfolding of eEF-2K627-725. Preliminary functional analyses indicate that neither a peptide encoding a region deemed crucial for eEF-2 binding nor isolated eEF-2K627-725 inhibits eEF-2 phosphorylation by full-length eEF-2K. Taken together, our data suggest that the extreme C-terminal region of eEF-2K, in isolation, does not provide a primary docking site for eEF-2.


    Organizational Affiliation

    Department of Chemistry and Biochemistry, The City College of New York , New York, New York 10031, United States.,Division of Chemical Biology and Medicinal Chemistry, University of Texas , Austin, Texas 78712, United States.,Graduate Program in Cell and Molecular Biology, University of Texas , Austin, Texas 78712, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Eukaryotic elongation factor 2 kinase
A
103Homo sapiensMutation(s): 0 
Gene Names: EEF2K
EC: 2.7.11.20
Find proteins for O00418 (Homo sapiens)
Go to Gene View: EEF2K
Go to UniProtKB:  O00418
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 400 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical SciencesUnited StatesGM084278
National Institutes of Health/National Institute of General Medical SciencesUnited StatesGM059802
Welch FoundationUnited StatesF-1390
United States Department of Education GAANNUnited StatesP200A120211
Alfred P. Sloan FoundationUnited States2014-6-25

Revision History 

  • Version 1.0: 2016-09-14
    Type: Initial release
  • Version 1.1: 2016-10-12
    Type: Database references
  • Version 1.2: 2017-09-27
    Type: Author supporting evidence, Database references, Structure summary
  • Version 1.3: 2018-01-17
    Type: Author supporting evidence